45.76
-1.75 (-3.68%)
| Penutupan Terdahulu | 47.51 |
| Jumlah Dagangan | 267,532 |
| Harga / Pendapatan (P/E Ke hadapan) | 19.64 |
| Harga / Jualan (P/S) | 5.78 |
| Harga / Buku (P/B) | 133.52 |
| Julat 52 Minggu |
| Margin Keuntungan | -125.70% |
| Margin Operasi (TTM) | -99.16% |
| EPS Cair (TTM) | -4.76 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 286.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1,016.89% |
| Nisbah Semasa (MRQ) | 8.25 |
| Aliran Tunai Operasi (OCF TTM) | -108.78 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -60.04 M |
| Pulangan Atas Aset (ROA TTM) | -15.14% |
| Pulangan Atas Ekuiti (ROE TTM) | -343.83% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | AnaptysBio, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.1 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | -5.0 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | -2.5 |
| Persekitaran Makro | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | -1.26 |
|
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 5.09% |
| % Dimiliki oleh Institusi | 133.99% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Ecor1 Capital, Llc | 30 Jun 2026 | 7,880,094 |
| Tang Capital Management Llc | 30 Jun 2026 | 1,330,879 |
| Affinity Asset Advisors, Llc | 30 Jun 2026 | 826,109 |
| Woodline Partners Lp | 30 Jun 2026 | 717,014 |
| 683 Capital Management, Llc | 30 Jun 2026 | 660,000 |
| Palo Alto Investors Lp | 30 Jun 2026 | 603,489 |
| First Light Asset Management, Llc | 30 Jun 2026 | 582,004 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |